Shopping Cart 0
Cart Subtotal
USD 0

Catalyst Pharmaceuticals Inc (CPRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops prescription drugs targeting rare neurological and neuromuscular diseases. The company focuses on specific conditions such as infantile spasms, complex partial seizures, Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), downbeat nystagmus and Tourette syndrome. Its product portfolio includes Firdapse, a proprietary form of amifampridine phosphate for the treatment of LEMS, CMS and myasthenia gravis; CPP-115, a GABA aminotransferase inhibitor for central nervous system (CNS) indications, such as infantile spasms, epilepsy and Tourette syndrome; and CPP-109, a generic version of Sabril for Tourette's disorder. Catalyst is headquartered in Coral Gables, Florida, the US.

Catalyst Pharmaceuticals Inc (CPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11

Equity Offering 13

Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13

Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15

Catalyst Pharma Completes Public Offering Of Shares For USD 28.7 Million 17

Catalyst Pharma Completes Public Offering Of Shares For USD 15 Million 19

Catalyst Pharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 20

Catalyst Pharma Completes Public Offering Of Shares For USD 6 Million 21

Catalyst Pharma Partners Completes Public Offering Of Units For USD 4.8 Million 22

Catalyst Pharmaceuticals Inc-Key Competitors 24

Catalyst Pharmaceuticals Inc-Key Employees 25

Catalyst Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Nov 07, 2018: Catalyst Pharmaceuticals announces third quarter 2018 financial results and provides corporate update 27

Aug 07, 2018: Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update 29

May 09, 2018: Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update 31

Mar 14, 2018: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 32

Nov 08, 2017: Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update 34

Aug 09, 2017: Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 35

May 10, 2017: Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 37

Mar 15, 2017: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 38

Corporate Communications 40

Aug 20, 2018: Catalyst Pharmaceuticals names Dr. Stanley Iyadurai as vice president of clinical development 40

Aug 06, 2018: Catalyst Pharmaceuticals expands commercial leadership team 41

Oct 26, 2017: Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11

Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13

Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15

Catalyst Pharma Completes Public Offering Of Shares For USD 28.7 Million 17

Catalyst Pharma Completes Public Offering Of Shares For USD 15 Million 19

Catalyst Pharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 20

Catalyst Pharma Completes Public Offering Of Shares For USD 6 Million 21

Catalyst Pharma Partners Completes Public Offering Of Units For USD 4.8 Million 22

Catalyst Pharmaceuticals Inc, Key Competitors 24

Catalyst Pharmaceuticals Inc, Key Employees 25

Catalyst Pharmaceuticals Inc, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Catalyst Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops prescription drugs targeting rare neurological and neuromuscular diseases. The company focuses on specific conditions such as infantile spasms, complex partial seizures, Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), downbeat nystagmus and Tourette syndrome. Its product portfolio includes Firdapse, a proprietary form of amifampridine phosphate for the treatment of LEMS, CMS and myasthenia gravis; CPP-115, a GABA aminotransferase inhibitor for central nervous system (CNS) indications, such as infantile spasms, epilepsy and Tourette syndrome; and CPP-109, a generic version of Sabril for Tourette's disorder. Catalyst is headquartered in Coral Gables, Florida, the US.

Catalyst Pharmaceuticals Inc (CPRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11

Equity Offering 13

Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13

Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15

Catalyst Pharma Completes Public Offering Of Shares For USD 28.7 Million 17

Catalyst Pharma Completes Public Offering Of Shares For USD 15 Million 19

Catalyst Pharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 20

Catalyst Pharma Completes Public Offering Of Shares For USD 6 Million 21

Catalyst Pharma Partners Completes Public Offering Of Units For USD 4.8 Million 22

Catalyst Pharmaceuticals Inc-Key Competitors 24

Catalyst Pharmaceuticals Inc-Key Employees 25

Catalyst Pharmaceuticals Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Nov 07, 2018: Catalyst Pharmaceuticals announces third quarter 2018 financial results and provides corporate update 27

Aug 07, 2018: Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update 29

May 09, 2018: Catalyst Pharmaceuticals Announces First Quarter 2018 Financial Results and Provides Corporate Update 31

Mar 14, 2018: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 32

Nov 08, 2017: Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update 34

Aug 09, 2017: Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 35

May 10, 2017: Catalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 37

Mar 15, 2017: Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 38

Corporate Communications 40

Aug 20, 2018: Catalyst Pharmaceuticals names Dr. Stanley Iyadurai as vice president of clinical development 40

Aug 06, 2018: Catalyst Pharmaceuticals expands commercial leadership team 41

Oct 26, 2017: Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Catalyst Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Catalyst Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Catalyst Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Catalyst Pharma Amends Licensing Agreement with BioMarin Pharmaceutical 11

Catalyst Pharma Raises USD57.5 Million in Public Offering of Shares 13

Catalyst Pharma Raises USD37.4 Million in Public Offering of Shares 15

Catalyst Pharma Completes Public Offering Of Shares For USD 28.7 Million 17

Catalyst Pharma Completes Public Offering Of Shares For USD 15 Million 19

Catalyst Pharma Completes Private Placement Of Shares For USD 1.1 Million Upon Exercise Of Warrants 20

Catalyst Pharma Completes Public Offering Of Shares For USD 6 Million 21

Catalyst Pharma Partners Completes Public Offering Of Units For USD 4.8 Million 22

Catalyst Pharmaceuticals Inc, Key Competitors 24

Catalyst Pharmaceuticals Inc, Key Employees 25

Catalyst Pharmaceuticals Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Catalyst Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.